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Shigella sonnei is the most common agent of shigellosis in high-income countries, and causes
a significant disease burden in low- and middle-income countries. Antimicrobial resistance is
increasingly common in all settings. Whole genome sequencing (WGS) is increasingly uti-
lised for S. sonnei outbreak investigation and surveillance, but comparison of data between
studies and labs is challenging. Here, we present a genomic framework and genotyping
scheme for S. sonnei to efficiently identify genotype and resistance determinants from WGS
data. The scheme is implemented in the software package Mykrobe and tested on thousands
of genomes. Applying this approach to analyse >4,000 S. sonnei isolates sequenced in public
health labs in three countries identified several common genotypes associated with increased
rates of ciprofloxacin resistance and azithromycin resistance, confirming intercontinental
spread of highly-resistant S. sonnei clones and demonstrating the genomic framework can
facilitate monitoring the spread of resistant clones, including those that have recently
emerged, at local and global scales.
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S higella spp are Gram-negative bacterial pathogens thatcause shigellosis (bacterial dysentery). Shigella are trans-mitted via the faecal-oral route and estimated to cause
~188 million infections annually, leading to ~160,000 deaths
mainly in young children1. In low- and middle-income settings,
most of the Shigella disease burden of shigellosis is in children
under five years2, however in high-income countries Shigella is
frequently detected in returned travellers or men who have sex
with men (MSM)3,4. Shigella sonnei is the most frequently isolated
agent of shigellosis in high-income countries and in those that
are economically developing1,5,6. S. sonnei emerged recently (~350
years ago7), share a single serotype, and display limited genomic
diversity (all belong to ST152 complex by multi-locus sequence
typing (MLST)). These properties make it difficult to differentiate
and track S. sonnei strains7, motivating adoption of whole-genome
sequencing (WGS) for research and public health surveillance of
this organism8. Core-genome MLST (cgMLST) is available via the
Escherichia coli scheme in EnteroBase9 but has not been widely
adopted for S. sonnei surveillance, and most public health labs and
research studies rely on the higher-resolution technique of single
nucleotide variant (SNV)-based phylogenetics analysis.
The global population of S. sonnei is divided into five major
lineages7,10. Several WGS studies have investigated regional S.
sonnei epidemiology and population structure, including in
Asia11–14, Australia4, the Middle East15, South America10, and
the United Kingdom16–18; and defined additional sub-lineage-
level phylogenetic groups of local epidemiological importance,
associated with features such as ciprofloxacin-resistance19,
transmission within Orthodox Jewish communities15, or trans-
mission amongst MSM4,17. S. sonnei from Asia, Europe, Australia
and North America have for >20 years been dominated by
Lineage 3 strains that are resistant to early first-line anti-
microbials (trimethoprim-sulfamethoxazole, tetracycline, and
streptomycin) due to the presence of antimicrobial resistance
(AMR) genes acquired horizontally via the small plasmid spA and
a chromosomal Tn7-like transposon7,20,21. Resistance to chlor-
amphenicol and/or ampicillin is also observed (e.g., via acquisi-
tion of the Shigella resistance locus (SRL)10,22). Reduced
susceptibility to fluoroquinolones has emerged on multiple
occasions and in multiple locations through acquisition of point
mutations within the quinolone resistance determining region
(QRDR) of gyrA7,11. Resistance to ciprofloxacin has emerged at
least once via the accumulation of three QRDR mutations (2 in
gyrA and one in parC) in a South Asian sublineage that has since
been detected on multiple continents12–14,23. Resistance to the
last few remaining drugs is increasing through the acquisition and
maintenance of plasmids carrying mph(A) and ermB (azi-
thromycin resistance) or extended-spectrum beta-lactamase
(ESBL) genes (ceftriaxone resistance), often in combination with
additional aminoglycoside resistance genes11,14,16,18,24.
In many countries, S. sonnei is a notifiable infection and subject
to public health surveillance and outbreak investigations, which
are increasingly conducted using WGS8,25–28. However, the lack
of a defined global genomic framework and accompanying gen-
otype nomenclature hampers both local reporting, outbreak
detection, and patterns of spread within regions. For example,
most S. sonnei WGS studies have reported which of the five
major lineages their novel isolates belong to, but have had
to download public reference genome data, construct whole
genome alignments, and infer phylogenies to achieve this basic
identification23,27. Studies of MSM S. sonnei in different settings
have designated different names for the same lineages4,16,18,
obscuring the fact that the same clones are spreading amongst
MSM communities in different countries, and the only way to
recognize this currently is through construction of whole-genome
phylogenies incorporating data from multiple prior studies29.
WGS-based genotyping frameworks based on single nucleotide
variants (SNVs) have been widely adopted for the bacterial
pathogens Mycobacterium tuberculosis30 and Salmonella enterica
serovar Typhi31, which display similarly low levels of genomic
diversity to S. sonnei. These frameworks enable fast and accurate
typing of clinical isolates from WGS data without the need for
time-consuming comparative genomics or phylogenetics, facil-
itating straightforward identification of (and cross-jurisdictional
communication about) epidemiologically important lineages
from WGS data.
Here, we describe the global population structure for S. sonnei
and (i) propose a hierarchical SNV-based genotyping scheme,
which we define using 1935 globally distributed genomes; (ii)
implement the scheme within the free and open-source
Mykrobe32 software alongside detection of genetic determinants
that are highly predictive of fluoroquinolone susceptibility phe-
notypes in S. sonnei28; and (iii) validate this approach to geno-
typing using an additional 2015 genomes that were sequenced in
public health laboratories and deposited in the publicly available
GenomeTrakr database. Code is available at https://github.com/
katholt/sonneityping. By applying this novel genotyping frame-
work to S. sonnei WGS data generated in public health labora-
tories on three continents, we demonstrate the utility of the new
scheme for tracking and reporting emerging AMR clones both
within and between jurisdictions.
Results
Defining phylogenetically informative genotypes for S. sonnei.
In order to define the global population structure and identify
clades and marker SNVs, we collated 1935 publicly available S.
sonnei genomes from eight studies4,7,10–13,15,16 as our “discovery”
dataset (see Supplementary Table 1). These genomes represent
isolates from 48 countries, collected between 1943 and 2018
(Fig. 1c, d, Table 1). The majority originate from Asia (32.4%),
Europe (29.3%), Australia (18.8%), or Latin America and the
Caribbean (17.4%) (Table 1). The data set is diverse in terms of
acquired AMR genes (median 9 per genome, range 0–21), and
includes 150 (7.8%) genomes known to be associated with MSM.
The recombination-filtered core-genome maximum likelihood
phylogeny inferred from these genomes (Fig. 1b) was robust
(median bootstrap support 100%) and exhibited the five
previously-described deep branching lineages7,10. Lineage 3 was
most common (86.9%), followed by Lineage 2 (10.7%), Lineage 5
(1.4%), Lineage 1 (0.9%) and Lineage 4 (n= 1). The pairwise
core-genome SNV distance distribution revealed peaks and
troughs which we used to set thresholds to define clusters at
different levels of resolution (Fig. 2a). A threshold of 600 pairwise
SNVs separated the five major lineages; troughs at 215 SNVs and
100 SNVs were used to define higher-resolution genetic clusters.
(A similar structure was recovered using hierarchical Bayesian
clustering of the SNV matrix using FastBAPS, but with less
consistent levels of divergence between clusters; see Supplemen-
tary Fig. 1). Mapping the pairwise SNV threshold-defined clusters
onto the phylogeny confirmed that each cluster corresponded to a
monophyletic group with 100% bootstrap support, which we
designate as clades (n= 29, using 215-SNV threshold) and
subclades (n= 96, using 100-SNV thresholds).
We used these cluster memberships to define hierarchical
genotypes with nomenclature in the form [lineage].[clade].
[subclade] (see Fig. 1a). Similar to the M. tuberculosis and S.
Typhi schemes, this hierarchical nomenclature facilitates easy
recognition of relationships between genotypes; e.g., subclades
3.6.1, 3.6.2, …, 3.6.N are sister groups in the whole-genome
phylogeny, nested within clade 3.6, which falls within Lineage 3
(see Fig. 1a). The median pairwise distance between genomes of
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the same clade or subclade was 138 or 47 core-genome SNVs,
respectively (Fig. 2b).
Whilst the discovery set is not a systematic sampling across
geographic regions, it can provide some preliminary insights into
the global distribution of S. sonnei genotypes. Lineages were
broadly distributed across continents (with the exception of
Lineage 5 and the singleton Lineage 4, see Fig. 1c, Supplementary
Data 1), however the majority of clades (n= 24, 83%) were
represented by isolates from just one (n= 16, 57%) or two (n= 7,
23%) continents. At the other extreme, clades 3.6 and 3.7 were
widely distributed, with representatives on all six continents
(Fig. 1b). Clades 3.6 and 3.7 were the most common overall (19%
and 62%, respectively) and accounted for the majority of S. sonnei
































































































































































































































































































































































































































































































Fig. 1 Population structure, temporal distribution and geographic distribution of the 1935 S. sonnei genomes in the discovery set. aMaximum likelihood
phylogeny (outgroup rooted using E. coli) of one representative per genotype. Lineages are labelled LX, where X is the lineage number. Highlighting and
column 1 indicate clades, column 2 indicates genotype, column 3 shows strain names, column 4 shows human readable genotype names (for
epidemiological groups noted in Table 2). b Maximum likelihood phylogeny (outgroup rooted using E. coli), c frequencies by geographic region, and
d frequencies by decade/year; for all discovery set genomes and coloured by lineage and major clades (3.6, 3.7, see inset legend). Interactive version of
linked phylogeny, map and timeline for this data set are available online in Microreact (https://microreact.org/project/fG2N7huk9oZNCaVHu8rukr).
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2.12, 3.4, 3.6 and 5.1 were common (8–28% each). Subclades
showed even greater geographic specificity, with 74% (n= 71)
represented by a single continent only and 72% (n= 69)
represented by a single region only. Fifty-nine subclades (61%)
were dominated by genomes from a single country.
As a key goal of the S. sonnei genotyping scheme is to facilitate
identification and communication about subtypes of public health
interest, we reviewed the position of genetic clusters that have
been described in the literature as being of epidemiological
importance (Table 2). Groups previously identified as being
associated with specific geographical regions mapped mainly to
clades or subclades defined in the genotyping scheme (Table 2).
Most groups previously defined on the basis of AMR or
transmission patterns comprised more recently-emerged clusters,
forming monophyletic groups within our subclade-level geno-
types. Hence we created additional higher-resolution genotypes
nested within subclades to demarcate these groups (e.g., 3.6.1.1,
3.6.1.1.1; see Table 2), and anticipate adding more genotypes as
new resistant groups emerge in future. For example, the
ciprofloxacin resistant triple-mutant sublineage12–14 comprised
a monophyletic group within subclade 3.6.1 that we define as
genotype 3.6.1.1; distinct subgroups within this have also been
described, associated with South East Asia (genotype 3.6.1.1.1),
and MSM communities in Australia (3.6.1.1.2) or the UK
(3.6.1.1.3.1) (see Table 2).
To facilitate communication about genotypes of epidemiolo-
gical interest, we also assigned them human readable aliases (e.g.,
3.6.1.1 = CipR, 3.6.1.1.1 = CipR.SEA, 3.6.1.1.2 = CipR.MSM5,
Table 1 Geotemporal distribution of 1935 S. sonnei genomes in the discovery dataset.
Region Country Year(s) of isolation No. of isolates
Africa Total 1967–2006 19 (0.98%)
Central Africa Cameroon 1973 1
East Africa Madagascar 1998–2000 3
Kenya, Tanzania 2004 2
Northern Africa Egypt 2005–2006 4
Morocco 2005–2006 4
West Africa Senegal 1967–2006 4
Burkina Faso 2006 1
Asia Total 1979–2014 627 (32.4%)
Central Asia Uzbekistan 2005 1
Eastern Asia Korea 1979–2003 20
Southern Asia Bhutan 2011–2013 71
India 2013–2014 24
Pakistan 2002–2003 7
Other (Nepal, Iran, Sri Lanka) 2003–2006 3
Southeast Asia Cambodia 2013–2014 4
Thailand 1994–2013 9
Vietnam 1995–2015 266
Western Asia Israel 1992–2014 222
Europe Total 1943–2016 567 (29.3%)




Western Europe France 1945–2014 158
Belgium 2008 3
Germany Unknown 1
Northern America Total 1994–2015 16 (0.8%)
North America USA 2004–2015 13
Other (unknown) 1994–1995 3
Latin America and
the Caribbean
Total 1997–2014 337 (17.4%)
Caribbean Cuba, Dominican Republic, Haiti 2003–2006 3
Central America Costa Rica 2002–2010 50
Guatemala 2011–2012 30
Mexico 1998 1











Total 1997–2018 364 (18.8%)
Australia Australia 2016–2018 363
Oceania New Caledonia 1997 1
Unknown Total Unspecified 5 (0.5%)
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see Table 2). As far as possible these aliases map to names given
in previous publications, e.g., the MSM clade numbers designated
in16,17. Most of the epidemiological groups of interest belong to
Lineage 3, and detailed phylogenies for these groups are provided
in Supplementary Fig. 2. In addition to being monophyletic on
the tree, these higher-level genotypes were supported by
FastBAPS analysis (Supplementary Fig. 1). Pairwise distances
within and between genotypes of all levels are shown in Fig. 2b.
Development and validation of SNV-based scheme for
assigning genotypes. We identified marker SNVs unique to each
genotype (147 SNVs in total, see Supplementary Data 2) and
implemented code to assign new genomes to genotypes based on
presence of these markers (see “Methods”). To validate this
approach, we downloaded and genotyped 2015 additional S.
sonnei genomes from GenomeTrakr (referred to as validation set,
see Supplementary Data 1). These genomes originate from public
health laboratories in three countries (n= 609 USA, n= 1325
UK, n= 11 Israel, n= 70 country unknown), with isolation dates
between 2015 and 2019.
We identified 17 different genotypes, all belonging to clades 3.6
or 3.7 (Supplementary Table 2). The vast majority (70%, n=
1403) belonged to clade 3.6. Genotype 3.6.1.1.2 (CipR.MSM5)
was the most prevalent, assigned to 26.6% of the genomes,
followed by 3.6.1.1 (CipR, 19.6%) (Supplementary Table 2). The
UK GenomeTrakr genomes yielded the greatest number of
genotypes (n= 16), followed by the USA (n= 13); likely due to a
high number of travel-associated cases. All GenomeTrakr
genomes deposited from Israel were identified as 3.7.30.4 (Israel
III, 9%) or 3.7.30.4.1 (OJC, 91%); these genotypes were also
detected amongst UK and USA genomes.
To verify the genotyping scheme accurately captured the
population structure present in the GenomeTrakr isolates, we
constructed a core-genome phylogeny including both the
validation set and Lineage 3 discovery set (total n= 3696
genomes, see “Methods”) and mapped the genotype assignments
to this tree (see Supplementary Fig. 3 and Microreact
https://microreact.org/project/g8BvA2JCXWaZNDyPyjsWXF).
All groups of isolates sharing a genotype assignment based on
marker SNVs constituted monophyletic clades within the core-
genome phylogeny, consistent with the expected behaviour of the
scheme. This was true for all levels in the hierarchical scheme,
including clades, subclades, and higher-resolution epidemiologi-
cal groups.
Distribution of antimicrobial resistance determinants amongst
S. sonnei genotypes. We used the genotyping scheme to facilitate
exploration of the distribution of AMR determinants in the global
S. sonnei population, by assessing the frequency of AMR genes
and QRDR SNVs across genotypes (Fig. 3). For this analysis we
included n= 6715 genomes: n= 1935 discovery set, n= 2015
validation set and a further n= 2765 public genomes (accessions


























Fig. 2 Distribution of SNV distances in discovery genomes. a Histogram of pairwise SNV distances between all discovery genomes, coloured by lineage
comparison as per legend. Red lines mark SNV cut-offs used to define lineage, clade and subclade levels in genotyping scheme. b Boxplots of pairwise SNV
distances (log scale, n= 1,873,081 pairwise distances) between discovery genomes at different hierarchical levels of the defined genotyping scheme. Boxes
indicate the median (bold line), 25th to 75th percentiles (box), and the 5th and 95th percentile (whiskers), with outliers shown as points. Lineage, Clade
and Subclade refer to the first three levels of the scheme. ‘4’ indicates the fourth level of the scheme (i.e., the final ‘1’ in 3.6.1.1), ‘5’ the fifth level (i.e., the ‘1’
in 3.7.30.4.1), and ‘6’ the sixth level (i.e., the final ‘1’ in 3.6.1.1.3.1).
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associated with specific genotypes, present amongst either all or
no members of each genotype (Supplementary Fig. 4).
Genes conferring resistance to first-line drugs were found in all
lineages. Those associated with the spA plasmid (sul2, tetA(A))
were found in all lineages but were most widely distributed across
clades of Lineage 3 (found in all clades) followed by Lineage 2
(81% of clades) (Fig. 3, Supplementary Fig. 4). Tn7 transposon
genes (tnsABCDE), the class II integron integrase (intA2) and
AMR genes in the integron cassette (satA2, dfrA1, aadA1) were
absent from Lineage 1 but found in Lineages 2 and 3 (40–41% of
clades) and the single Lineage 5 clade (Fig. 3). This combination
of markers for the chromosomally integrated MDR transposon
Tn7 was most common in clades 3.6 (99%), 3.7 (99%) and 2.12
(88%), where it was typically accompanied by spA genes (sul2,
tetA(A)) resulting in resistance to co-trimoxazole (Fig. 3). First-
line AMR genes aadA1, tetA(B), catA1 and blaOXA-1, which are
known to mobilise together on the SRL, co-occurred in clades 3.3,
3.4 and 3.5, consistent with prior reports of SRL in clade Latin
America IIIa (3.4)10. Acquired genes blaTEM-1 and sul1 were also
found at low frequencies across diverse genotypes (Supplemen-
tary Fig. 4), suggesting occasional acquisition via mobile elements.
QRDR SNVs were detected in 50.4% of all genomes, distributed
across six clades and 12 subclades (Fig. 3), consistent with
frequent emergence of these mutations under selection from
drug exposure. Most common was GyrA-S83L (42% of genomes,
six clades, 12 subclades) followed by GyrA-D87G (30.8% of
genomes, five clades, ten subclades). Single mutants were most
common (18.7% of genomes, five clades, 6 subclades) but double
mutants were also observed in 3.6.1 (n= 61/6715 genomes had
GyrA-S83L+GyrA-D87G). QRDR triple mutants, associated
with ciprofloxacin resistance, were detected only in the CipR
sublineage (genotype 3.6.1.1) which harbours GyrA-S83L+GyrA-
D87G+ParC-S80I. The emergence and evolutionary dynamics of
this CipR sublineage from within the Central Asia IIIa clade
(genotype 3.6) were recently described in a detailed phylodynamic
study of fluoroquinolone resistant isolates from diverse sources by
The et al.14. That study divided the Central Asia III clade into two
populations: Pop1, with either GyrA-D87Y or GyrA-S83L arising
on two independent occasions in South Asia in the mid-1990 s; and
Pop2, which arose from Pop1 genomes carrying GyrA-S83L in
South Asia in the early 2000s, and then acquired GyrA-D87G and
ParC-S80I to become fluoroquinolone resistant before spreading
geographically14. Applying our new genotyping scheme to the
genomes from The et al.14 (Supplementary Fig. 5), we confirm that
Pop1 maps to clade 3.6 (n= 18) and its subclades 3.6.1, 3.6.2, 3.6.3,
3.6.4; and Pop2 maps to sublineage 3.6.1.1 (CipR, n= 239)
including its subgroups 3.6.1.1.1 (CipR.SEA, n= 30), 3.6.1.1.2
(CipR.MSM5, n= 3), 3.6.1.1.3 (n= 16) and 3.6.1.1.3.1 (CipR.
MSM1, n= 19).
Determinants of resistance to azithromycin and extended-
spectrum cephalosporins were rare and concentrated mainly in
clades 3.6 and 3.7. The plasmid-borne azithromycin resistance
Table 2 Details of epidemiological clusters defined within the S. sonnei population.
New genotyping
framework
Previously defined as Description
Genotype Name Name Study
Lineage II
2.8 Korea II Korea II Holt 2012 Associated with Korea
2.9, 2.10, 2.11 Latin America II South America II
LA sublineage IIa & IIb
Holt 2012
Baker 2017
Associated with Latin America
Lineage III
3.4 Latin America III South America III
LA sublineage IIIa & IIIb
Holt 2012
Baker 2017
Associated with Latin America
3.6 Central Asia III Central Asia IIIa Holt 2012 Associated with Central Asia








3.6.1.1.1 CipR.SEA - This study Ciprofloxacin-resistant isolates associated
with South East Asia





MSM-linked ciprofloxacin resistant isolates
3.7.25 MSM4 MSM Clade 4 Baker 2018 MSM-linked
3.7.29 Vietnam III VN clone Holt 2012 Associated with South East Asia
3.7.29.1 VN2 VN clone, sweep 2 Holt 2013 Clonal group originating from genetic sweep 2
3.7.29.1.1 VN3 VN clone, sweep 3 Holt 2013 Clonal group originating from genetic sweep 3
3.7.29.1.1.1 VN3.KH2 KH2 Holt 2013 Kanh Hoa subclone 2, emerging from sweep 3
3.7.29.1.1.2 VN4 VN clone, sweep 4 Holt 2013 Clonal group originating from genetic
sweep 4





Australian MSM-linked, emerging from
sweep 2
3.7.29.1.3 VN2.Hue Hue2 Holt 2013 Hue subclone 2, emerging from sweep 3





Australian isolates, emerging from KH1
3.7.30 Middle East III Middle East III Holt 2012 Associated with Middle East
3.7.30.4 Israel III Israel III This study Associated with Israel
3.7.30.4.1 OJC OJC-associated Baker 2016 Associated with the Orthodox Jewish
communities in Israel, UK, USA and Europe
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genes mph(A) and ermB were detected at high frequency in
genotypes 3.6.1.1.2 (CipR.MSM5, n= 915, 95%) and 3.7.29.1.2.1
(VN2.MSM2.Aus, n= 147, 90%); mph(A) was present alone in
the single 1.2.1 genome (Vietnam, 2007), and alone or with ermB
at lower frequency (<65%) amongst other Lineage 3 genotypes
(Fig. 3). Notably, n= 947 3.6.1.1 (CipR) genomes carried mph(A)
in addition to Tn7 and spA genes, rendering them resistant
to azithromycin, ciprofloxacin and first-line drugs (n= 58, 3.6.1;
n= 16, 3.6.1.1; n= 868, 3.6.1.1.2; n= 2, 3.6.1.1.3; n= 3,
3.6.1.1.3.1), leaving extended-spectrum cephalosporins as the last
remaining oral drug. ESBL genes were detected only sporadically,
at low frequencies in clades 3.6 (13%) and 3.7 (12%), across 25
distinct genotypes (frequency range, 0.6–100%, median 17.2%)
(see Fig. 3). Carbapenemase genes were extremely rare, present in
only two genomes (blaOXA-66 and blaOXA-181). Concerningly, we
detected 40 genomes with resistance determinants for azithro-
mycin, third-generation cephalosporins and fluoroquinolones,
all within CipR genotype 3.6.1.1 (n= 16, 3.6.1.1; n= 11, 3.6.1.1.1;
n= 15, 3.6.1.1.2). These genomes were isolated between 2014 and
2019, and were found in genomes from England (n= 21),
Australia (n= 13), the USA (n= 3), Vietnam (n= 3) and the
Netherlands (n= 2) (further details below).
Tn7 spA other mobile elements QRDR mutationsSRL






















































































































































































































































































































































Fig. 3 Frequencies of AMR genetic determinants within individual S. sonnei genotypes, calculated across 6715 genomes. Cells indicate absence (white)
or presence (coloured by proportion as per legend) of each AMR determinant (columns) within each clade or higher-resolution genotype (rows). All clades
are included as rows (bold labels); subclades and higher-resolution genotypes represented by ≥10 genomes are also included as distinct rows; number of
genomes in each row are noted in column “N”. Light blue shading indicates fluoroquinolone resistant genotypes; dark blue shading indicates MSM-
associated genotypes. Columns are grouped by typical location of the AMR determinant (labelled horizontal bars at the top): transposon Tn7, represented
by marker genes tnsABCDE and class II integron In2 integrase gene intA2; Shigella resistance locus (SRL); spA plasmid, represented by marker gene rep;
other mobile elements; mutations in quinolone resistance determining region (QRDR). Column “other Agly” indicates proportion of genomes carrying at ≥1
additional aminoglycoside resistance gene beyond those with their own columns; column ‘other’ indicates proportion of genomes carrying ≥1 other AMR
gene that is not otherwise listed (full AMR gene content per strain is available in Supplementary Data 1).
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Application to public health surveillance data from Australia,
England and USA. To demonstrate how the S. sonnei genotyping
framework can facilitate the rapid tracking and reporting of
emerging AMR trends across jurisdictions, we applied it to
genomic surveillance data from Victoria, Australia (n= 644),
England (n= 2867) and USA (n= 711) generated over a 4-year
period (2016–2019) (data in Supplementary Data 1). The data
represents all cultured isolates submitted to the Microbiological
Diagnostic Unit Public Health Laboratory in Australia (42% of all
S. sonnei notifications in Victoria)4 and all those sent to the
Public Health England Gastrointestinal Bacteria Reference Unit28
(provided direct from the reference laboratories for the present
study); and ~5% of those notified in the USA (sourced from the
public GenomeTrakr database33). The total time taken to gen-
erate genotyping reports (including QRDR mutations) for all n=
4222 isolates was ~40 sec – 1 min per isolate using Mykrobe, with
raw Illumina sequence files (fastq format) as input.
Figure 4a shows the annual frequency of fluoroquinolone
resistance (defined as presence of 3 QRDR mutations) in each
country, and the distribution of genotypes amongst the resistant
isolates. Increasing fluoroquinolone resistance rates are evident
amongst the S. sonnei samples from each country, beginning at
≤25% in 2016 and reaching 85% in Australia, 39% in England and
44% in USA in 2019 (black lines, Fig. 4a). All fluroquinolone
resistant genomes belonged to genotypes within the CipR
sublineage (3.6.1.1), with the subgroup 3.6.1.1.2 (CipR.MSM5)
accounting for a steadily increasing proportion of resistant
isolates in each country, from ≤30% in 2016 to 78% in Australia,
59% in England and 85% in USA in 2019 (pink bars, Fig. 4a).
These results are consistent with local epidemiological outbreaks
of S. sonnei in MSM communities in England16,17 and
Australia4,26. Notably however, the common nomenclature makes
it easy to identify several epidemiologically important patterns: (i)
all resistant isolates in all three countries derive from the
previously-described CipR sublineage 3.6.1.1 that emerged from
South Asia in the early 2000s; (ii) the reported spread of resistant
S. sonnei in MSM communities in Australia and England involves
the same strain (this was not clear from previous reports, as the
strain was named “MSM clade 5” in the English studies and
formed a subgroup within the “BAPS3 cluster” in the Australian
studies); (iii) this strain represents a clonal subgroup of the CipR
sublineage (genotype 3.6.1.1.2, CipR.MSM5) that has dissemi-
nated intercontinentally over the last few years and become
responsible for the majority of fluoroquinolone resistant S. sonnei
infections in all three countries. (Note an additional two English
isolates of genotype 3.6.1.1 from 2019 carried gyrA-S83L and
parC-S80I plus the qnrS gene, which likely combine to confer
fluoroquinolone resistance34).
Figure 4b shows the annual frequency of azithromycin
resistance (predicted by presence of mph(A)) in each country,
and the genotypes responsible. Resistance rates were high (>50%)
in Australia across the whole period, reflecting documented
outbreaks in the MSM community4. In England and the USA,
rates increased between 2016 and 2019, from 13 to 38% in
England and 15 to 45% in the USA (black lines, Fig. 4b). The
genotype distributions amongst mph(A)+ genomes differed
markedly between countries in 2016, dominated by 3.7.29
(VNclone, 95%) in Australia, 3.7.25 (MSM4, 32%) and 3.6.1.1.2
(CipR.MSM5, 36%) in England, and 3.6.1.1 (CipR, 46%), 3.7.29
(VNclone, 31%) and 3.6.1.1.2 (CipR.MSM5, 23%) in the USA (see




































































































Fig. 4 Prevalence and genotype breakdown of ciprofloxacin and azithromycin resistant S. sonnei in three surveillance regions (Australia, England and
USA) from 2016 to 2019. In each plot, black lines indicate the proportion of genomes that are predicted resistant to (a) ciprofloxacin (defined as presence
of ≥3 QRDR mutations) or (b) azithromycin (defined as carrying mph(A)). Error bars indicate 95% confidence intervals for the proportion resistant (n=
144–182 for Australia, n= 610–869 for England, n= 87–313 for USA). Stacked bars indicate the relative abundance of each genotype among resistant
isolates, coloured by genotype as per legend.
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barplot, Fig. 4b). Notably though, the contribution of 3.6.1.1.2
(CipR.MSM5) increased dramatically in each country, and in
2019 accounted for 99% of mph(A)+ isolates in Australia, 62% in
England and 93% in USA (bars, Fig. 4b). Thus in 2019, the
majority of predicted azithromycin resistant isolates in all three
countries were also predicted to be resistant to ciprofloxacin and
first line drugs. Concerningly, the proportion of total S. sonnei
genomes with combined resistance determinants for azithromy-
cin, ciprofloxacin and first-line drugs was high (36–66%) in all
three countries in 2019 (Fig. 5).
Whilst ESBL genes were rare across the S. sonnei surveillance
data (7.8% in Australia, 17.5% in England, 1% in USA, see
Supplementary Data 1), concerningly 201 genomes carried ESBL
genes in addition to mph(A), and 36 of these were QRDR triple
mutants belonging to 3.6.1.1 (CipR). The latter were concentrated
in genotypes 3.6.1.1, 3.6.1.1.1 and 3.6.1.1.2 and comprised 13
Australian genomes (2% of total, 2016–2019, all three genotypes),
20 English genomes (0.7% of total, in 2016 and 2018–2019, all
three genotypes) and 3 USA genomes (0.4% of total, 2017, only
3.6.1.1 and 3.6.1.1.1) (Fig. 5). Consistent with the overall picture
of ESBL genes in S. sonnei described above (Fig. 3), there was no
evidence of strong linkage between specific ESBL genes and
particular genotype backgrounds in the public health surveillance
data for this period (Supplementary Data 1). This was true even
amongst CipR/AziR/ESBL+ genomes, which included eight
unique combinations of genotype and blaCTX-M allele (3–6 per
country, Supplementary Fig. 6), consistent with multiple
independent acquisitions of different AMR plasmids in different
settings contributing to the march towards pan-resistance to
oral drugs.
Discussion
Here, we provide a global framework for S. sonnei, and identify
marker SNVs that can be used to easily position newly sequenced
isolates into this framework, without the need for time-
consuming comparative genomics or phylogenetic analysis. We
demonstrate that the population structure of S. sonnei can be
represented by a robust maximum likelihood phylogeny and
define within it 137 subtrees on the basis of pairwise divergence
and epidemiological coherence, which we designate as hier-
archically nested genotypes. Furthermore, we provide a software
package implemented within the Mykrobe32 code base, which can
identify both the S. sonnei genotype and QRDR SNVs direct from
short-read sequence files in a few seconds.
The genotyping scheme was constructed with a view towards
stability, prioritising as markers SNVs that are found in highly
conserved core genes that are not under adaptive selection in the
population. We also endeavoured to make the scheme backwards
compatible by identifying and designating unique genotypes for S.
sonnei genetic clusters defined in previous studies on the basis of
epidemiological features (see Table 2). We further aimed to
ensure genotypes are interpretable, with stable numerical identi-
fiers that convey relationships between genotypes, and human
readable aliases that convey relevant epidemiological information
where appropriate (see Table 2). The genotyping scheme can be
readily expanded in future, by adding new genotypes and corre-
sponding SNV markers as new clusters of agreed epidemiological
importance are identified based on phylogenetic analyses. We
envisage managing future updates via an international working
group consisting of epidemiological, public health and genomics
experts who utilise the scheme, similar to the approach proposed
for a recent Neisseria gonorrhoeae typing scheme35, and have
adopted clear versioning to facilitate compatibility between
laboratories and over time. Importantly, our approach provides
genotype definitions and nomenclature that are stable and
transparent, not dependent on comparative analysis or on any
specific sequencing assay or software package, although we pro-
vide an implementation in the Mykrobe v0.9.0 software for
convenience. The Mykrobe implementation was tested on all
Illumina reads used in this study, and matching long (ONT) reads
for eight of these genomes. Correct genotypes were returned in all
cases (providing the --ont flag to Mykrobe when using the long
reads as input). This overall approach is designed to facilitate easy
communication between laboratories and jurisdictions, and
straightforward comparison of pathogen populations over time,
allowing for rapid identification of clonal dissemination and
AMR trends.
To demonstrate the utility of the genotyping scheme for public
health applications, we applied it to summarise large genomic
surveillance datasets from three jurisdictions in Australia, Eng-
land and the USA. The results provide a straightforward view of
temporal trends in the populations of S. sonnei causing disease in
each jurisdiction. They also clearly identify common cipro-
floxacin and azithromycin resistant clones that have spread
globally and are now present in all three jurisdictions, which was
previously not obvious from individual studies, as there was no
common nomenclature.
The genotyping approach introduced here could greatly sim-
plify the bioinformatics procedures required for routine genomic
surveillance of S. sonnei in reference laboratories, the first step of
which usually involves comparison of newly sequenced genomes
to those from prior cases in the same jurisdiction (to monitor
local trends) and/or other jurisdictions (to monitor introduction
of new strains and patterns of regional spread). Notably, the
public health labs in Australia, England and USA from which we
sourced genomic surveillance data (Fig. 4) all utilise genome-wide
SNV-based phylogenetics for S. sonnei analysis17,26.
Reliance on whole genome comparisons and phylogenetic
inference is considerably slower than genotyping and requires
expertise and background knowledge both to conduct the analysis
and to interpret the results. In contrast, using the genotyping
framework, raw sequence data can be turned into simple infor-










































Fig. 5 Prevalence of combined resistance to ciprofloxacin and
azithromycin amongst genomes from each surveillance region. Stacked
bar colours indicate the relative abundance of different combinations of
resistances, predicted from genomes: CipR, ciprofloxacin resistant (defined
as presence of ≥3 QRDR mutations); AziR, azithromycin resistant (defined
as carrying mph(A)); ESBL+, presence of extended-spectrum beta-lactamase
(ESBL) gene associated with resistance to third generation cephalosporins
(blaCTX-M-14, blaCTX-M-15, blaCTX-M-27, blaCTX-M-55, blaCTX-M-134).
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genomes or databases (and without needing to assemble the
genome). The resulting genotyping information can be easily
interpreted, compared and stored in (non-sequence) databases for
future reference, facilitating epidemiological investigations with-
out need for direct comparisons with any other genome
sequences. Detailed phylogenetic analysis can then be applied to
subsets of isolates that share the same or similar genotypes, if
needed to address specific questions (e.g., relating to emerging
local outbreaks or transmission networks). Notably, such phylo-
genetic analyses are essential to identify the emergence of novel
clusters from within currently defined genotypes. If a high-quality
S. sonnei genome sequence lacked all the lineage-specific SNV
markers in the genotyping scheme, this would suggest it belongs
to a novel lineage. Such cases could be investigated further using
phylogenomics, and the scheme expanded to include the novel
lineage. While this is expected to be rare, it may well occur as
more sequencing is undertaken in Africa and other regions cur-
rently under-represented by the available genomic data.
For example, scientists investigating azithromycin-resistant S.
sonnei isolated from MSM in Switzerland recently reported iden-
tifying the strains as belonging to the same clones spreading
through MSM communities in England. To achieve this identifi-
cation, they had to download English genome data, compare their
newly isolated genomes to these using read mapping, and construct
and interpret whole genome phylogenies29. A similar study using
WGS to investigate a ciprofloxacin-resistant outbreak in California
used the same informatics approach to conclude that the local strain
belonged to the previously described ciprofloxacin resistant lineage
originating in South Asia23. Another recent study from Switzerland
used WGS to investigate an increase in ESBL S. sonnei using a
combination of cgMLST and phylogenetics36. Using our new gen-
otyping approach, all of these identifications could be made within
minutes of obtaining sequence data, with no need for external
comparative data, background knowledge of S. sonnei genetics, or
complex computational infrastructure and expertise (see Supple-
mentary Note 1, Supplementary Fig. 7, Supplementary Table 3 and
Supplementary Data 3). The rapid identification of genomically-
related isolates via genotyping could be used to facilitate timely
public health responses to shigellosis outbreaks.
A potential alternative to SNV-based genotyping is cgMLST,
available for Shigella/E. coli via EnteroBase9. The scheme consists
of 2513 genes as markers (~half the genome), including loci
under positive selection such as gyrA and parC, which are used to
define core genome sequence types (cgSTs). EnteroBase also
assigns cgSTs to hierarchical clusters (HC) with stable names,
using the HierCC algorithm9, at various locus-distance thresholds
(2, 5, 10, 20, etc). HC5 is widely used for detecting outbreak
clusters of Salmonella and E. coli in foodborne surveillance37–41,
however clustering of S. sonnei at HC5 (or even HC10) breaks
apart epidemiologically recognised outbreak clusters such as the
MSM clades 3.6.1.1.3.1 (CipR.MSM1), 3.6.1.1.2 (CipR.MSM5)
and 3.7.25 (MSM4) (see Supplementary Fig. 8), making them
hard to track. We speculate that the over-division of S. sonnei by
cgMLST may be due to the fact that many alleles are affected by
deletion or insertion sequence activity, as is common in S.
sonnei42. Notably our focused genotyping scheme is designed to
utilise a small number of highly stable loci, avoiding this issue. In
addition, cgST numbers and HierCC cluster numbers are arbi-
trarily assigned and carry no meaning beyond being unique
identifiers, whereas hierarchical naming systems such as those
used in our scheme (and those adopted for M. tuberculosis, S.
Typhi and SARS-CoV-243 schemes) are much more informative
as they communicate relationships between clusters. Perhaps for
these reasons, there is to-date only one published report of S.
sonnei analysis that utilised cgMLST for public health
investigation36, and they too relied on additional SNV-based
phylogenetics to place their local isolates in the context of global
populations as this was not easily ascertained using cgMLST (see
Example 2 in Supplementary Note 1, Supplementary Data 3).
In conclusion, while genomics is increasingly becoming a
standard tool for surveillance of S. sonnei and other pathogens in
public health reference laboratories, this poses computational and
epidemiological challenges in terms of analysis, interpretation and
communication of genome-derived data across discipline and
jurisdictional boundaries. The genotyping framework and uni-
versal nomenclature for S. sonnei established here provides a
solution for many of these issues, and provides a structure to
enable clear communication between public health and basic
science research groups. Importantly, it will facilitate monitoring
of the emergence and spread of AMR S. sonnei clones, at local
and global levels, which will become increasingly important as
public health agencies face the emerging threat of pan-resistant S.
sonnei.
Methods
Single nucleotide variants (SNVs) and phylogenetic analysis – discovery
dataset. The discovery dataset consisted of 1935 high quality previously published
S. sonnei genomes, sequenced using Illumina platforms. Source information for all
genomes (year of collection, geographic origin, etc) was extracted from their
respective publications4,7,10–13,15,16 (Supplementary Table 1 and Supplementary
Data 1). Genomes were mapped to the S. sonnei reference genome 53 G (accession
NC_016822) using RedDog (v1beta11; https://github.com/katholt/RedDog). Briefly,
RedDog maps reads with Bowtie2 v2.2.944 with the sensitive local parameter, then
uses SAMtools v1.145 to retain high quality SNV calls (phred score ≥20, read depth
>5, removes heterozygous calls). SNVs detected in repetitive regions where SNV
calls are dubious (e.g. insertion sequences, phage) were removed (see Figshare,
https://doi.org/10.26180/5f1a443b19b2f). SNVs associated with recombination were
identified and excluded using Gubbins v2.3.246 (n= 208 SNVs across 10 genomes).
The final alignment consisted of 23,673 SNVs across 1935 genomes. Ancestral
alleles at these SNV sites were extracted from five E. coli genomes (accessions
CP019005, CP031916, CP019961, CP034399 and CP019259) using the mapping
procedure described above, and were included in the alignment for the purpose of
outgroup rooting the tree. A maximum likelihood (ML) phylogeny was inferred
using IQ-TREE v247 using a GTR substitution model (Fig. 1b). An interactive form
of the tree is available in Microreact, at https://microreact.org/project/
fG2N7huk9oZNCaVHu8rukr.
Defining clades and subclades of the genotyping scheme. The discovery set was
analysed to define appropriate SNV thresholds for assigning genomes to genotypes
based on pairwise genetic distances. Pairwise SNV distances were calculated for all
pairs of, and thresholds were selected by examining the distribution of pairwise
SNV distances (Fig. 2a), to define clusters at three levels: lineage (600 SNVs), clade
(215 SNVs) and subclade (100 SNVs). To cluster discovery set genomes at these
thresholds, we applied hierarchical clustering (using hclust function in R, with
complete linkage) to the pairwise SNV distance matrix. The resulting dendrogram
was then cut at the aforementioned thresholds (using the R function cutree) to
cluster isolates into discrete groups representing lineages, clades and subclades. The
resulting groups were compared to the ML phylogeny to check that each was
monophyletic (using the function is.monophyletic in the ape package48 for R); a
small number of groups were non-monophyletic and were broken up into smaller
groups (2 groups at clade level, n= 388 isolates; 3 groups at subclade level, n= 52
isolates) to result in a final set of monophyletic clusters. The SNV alignment was
also analysed using the R package fastbaps49 to partition the data into groups using
Bayesian clustering (using the hc method for prior optimisation, and two levels of
clustering using multi_res_baps) (Supplementary Fig. 1a). Pairwise SNV distances
within and between our final genotype groups (Fig. 2b), and within and between
FastBAPS clusters for comparison (Supplementary Fig. 1b), were calculated from
the SNV alignments using the dna.dist function in the ape package48. Isolates
belonging to previously defined epidemiological groups were located in the ML
tree, and used to identify subtrees corresponding to each set of group members. For
epidemiological groups defined on the basis of AMR determinants, the presence of
these determinants (identified using SRST250 and the QRDR SNVs) was used to
determine the boundaries of the local subtree sharing the defining features of the
group (Table 2).
Developing and implementing SNV-based genotyping scheme. We identified
potential marker SNVs for each of the 147 genotypes by mapping SNVs onto the
branches of the ML phylogeny using SNPPar51 with default parameters. A total of
980 homoplasic SNVs were identified and excluded from consideration as markers.
For most genotypes multiple markers mapped to the defining branch; we priori-
tised synonymous changes within core genes (n= 138) over nonsynonymous (n=
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8) or intergenic SNVs (n= 1), and where multiple synonymous SNVs were
available we prioritised genes with the lowest ratio of nonsynonymous:synonymous
SNVs (calculated from SNPPar output) as these are less likely to be under selection
in the population and thus serve as stable marker SNVs. The list of SNV markers is
given in Supplementary Data 2.
We modified the Mykrobe genotyping software32 to probe for these marker
SNVs and assign S. sonnei genotypes. Probes to detect changes at specific S. sonnei
QRDR codons (GyrA-83, GyrA-87, ParC-80) were also included in the S. sonnei
panel in Mykrobe32 (v0.9.0) software available at https://github.com/Mykrobe-
tools/mykrobe, using the probe panel stored in Figshare (https://doi.org/10.6084/
m9.figshare.13072646). Mykrobe outputs were then parsed using a custom
Python script which tabulates results across a set of samples and summarises the
support for each genotype call (https://github.com/katholt/sonneityping). We
tested the Mykrobe S. sonnei genotyper using the discovery genome set as input
(Illumina reads, fastq format), to confirm that the genotype and QRDR mutations
reported by this implementation were correct. Code was also tested using Oxford
Nanopore (ONT) long reads (fastq format) using the --ont flag in Mykrobe.
Validating the genotyping scheme on independent data. We used an inde-
pendent validation dataset (i.e., genomes not included in the discovery set used to
define the scheme) a total of 2015 S. sonnei genomes downloaded from the Gen-
omeTrakr project33 on 7 May 7 2019 (listed in Supplementary Data 1). All gen-
omes had been sequenced using Illumina platforms. The validation and discovery
datasets were subjected to mapping, SNV calling and phylogenetic analysis as
described above, generating a recombination-filtered core-genome alignment of
32,138 SNVs in 3696 isolates (n= 260 SNVs identified as recombinant across 11
genomes), and a ML phylogeny (Supplementary Fig. 3, interactive tree available in
Microreact at https://microreact.org/project/g8BvA2JCXWaZNDyPyjsWXF). All
genomes were assigned a genotype using Mykrobe32 v0.9.0, and these were com-
pared to the ML phylogeny to check that each genotype was monophyletic as
expected (using the function is.monophyletic in the ape package48 for R). In
addition, we confirmed that all marker SNVs remained non-homoplasic amongst
this larger set of genomes, using output from SNPPar (a total of 2003 homoplastic
SNVs were identified amongst this expanded set of genomes).
Analysis of AMR determinants amongst genotypes. Genotypes were identified
as above, and AMR determinants were identified using SRST250 and the CARD
database52 for a further 2644 genomes sourced from public databases, and results
combined with those from the discovery and validation sets yielding a total of n=
6595 S. sonnei genomes for analysis. Genotypes with at least ten representatives in
this data set (total n= 57 genotypes), and AMR genes detected in at least two
genomes, were included in the analysis of AMR frequencies within genotypes
(Fig. 3 and Supplementary Fig. 4). Data were analysed in R and visualised using the
pheatmap and ggridges packages.
To assess the correspondence between genotypes defined here within the CipR
clade (genotype 3.6.1.1 and its subtypes) and the two subpopulations (Pop1, Pop2)
defined previously by The et al.14, we constructed a ML phylogeny including all
genomes analysed in The et al.14 and at least one representative from each Lineage 3
clade and each genotype in clade 3.6. Genomes which had not already been included
in the discovery set were genotyped, and subjected to mapping and SNV calling for
inclusion in phylogenetic analysis as described above, generating an alignment of
9178 SNVs and an ML phylogeny (Supplementary Fig. 5, interactive tree available in
Microreact at https://microreact.org/project/kMRoFFXxkB6JAn9bgBAdMz).
Application to public health surveillance data. We applied the S. sonnei geno-
typing framework to analyse 4222 genomes sequenced by public health reference
labs between 2016 and 2019 in Australia (n= 6444), England (n= 286716,17), and
the USA (n= 711, from GenomeTrakr33 as of 7 May 2019). All genomes were
genotyped, and AMR determinants were identified as above. Azithromycin resis-
tance was predicted based on presence of mph(A), ESBL/carbapenemase produc-
tion based on known beta-lactamase alleles (CTX-M, OXA-66, OXA-181), and
ciprofloxacin resistance based on the combination of three QRDR mutations
(GyrA-S83L, GyrA-D87Y and ParC-S80I). Data were analysed in R and visualised
using the ggplot2 package (Figs. 4–5).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
Supplementary Data 1 lists all genome data used, with read accessions, source
information, genotype calls and AMR determinants
Marker SNVs used to define genotypes are tabulated in Supplementary Data 2 and
GitHub, https://doi.org/10.5281/zenodo.4609813; and in Mykrobe panel format in
Figshare, https://doi.org/10.6084/m9.figshare.13072646
AMR genes were detected from CARD database v3.0.8, available at https://card.
mcmaster.ca/download
Regions of the S. sonnei 53 G reference genome excluded from SNV calling are
available in Figshare, https://doi.org/10.26180/5f1a443b19b2f





Mykrobe v0.9.0 is available for download at https://github.com/Mykrobe-tools/mykrobe
Instructions for running Mykrobe v0.9.0 for S. sonnei and tabulating the results is
available at https://github.com/katholt/sonneityping (https://doi.org/10.5281/
zenodo.4609813)
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